Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: A Pilot Study | Zendy

Lakshmi Goudhaman | Zendy; Anusha Raja Jagadeesan | Zendy; Saranya Sundaramoorthi | Zendy; Spandana Thotla | Zendy; Krishna Mohan Surapaneni | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: A Pilot Study

Author(s) -

Lakshmi Goudhaman,

Anusha Raja Jagadeesan,

Saranya Sundaramoorthi,

Spandana Thotla,

Krishna Mohan Surapaneni

Publication year - 2021

Publication title -

reports of biochemistry and molecular biology

Language(s) - English

Resource type - Journals

ISSN - 2322-3480

DOI - 10.52547/rbmb.10.2.302

Subject(s) - asymmetric dimethylarginine , medicine , coronary artery disease , cardiology , endothelial dysfunction , coronary atherosclerosis , nitric oxide , arginine , biochemistry , chemistry , amino acid

Asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide synthase (NOS), has been implicated in endothelial dysfunction and atherogenesis. Though there is much evidence linking ADMA with atherosclerosis and adverse cardiovascular events, only a few studies have established the independent relationship between elevated ADMA and the angiographic extent of coronary artery disease (CAD). The aim of the study was to analyze serum ADMA levels in patients with varied extent and severity of coronary atherosclerosis and to see whether the levels of ADMA in male and female participants vary significantly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research